GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vertex Pharmaceuticals Inc (BSP:VRTX34) » Definitions » Cyclically Adjusted PS Ratio

Vertex Pharmaceuticals (BSP:VRTX34) Cyclically Adjusted PS Ratio : 21.11 (As of Apr. 28, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Vertex Pharmaceuticals Cyclically Adjusted PS Ratio?

As of today (2024-04-28), Vertex Pharmaceuticals's current share price is R$509.49. Vertex Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 was R$24.14. Vertex Pharmaceuticals's Cyclically Adjusted PS Ratio for today is 21.11.

The historical rank and industry rank for Vertex Pharmaceuticals's Cyclically Adjusted PS Ratio or its related term are showing as below:

BSP:VRTX34' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 14.8   Med: 27.13   Max: 43.87
Current: 20.07

During the past years, Vertex Pharmaceuticals's highest Cyclically Adjusted PS Ratio was 43.87. The lowest was 14.80. And the median was 27.13.

BSP:VRTX34's Cyclically Adjusted PS Ratio is ranked worse than
83.76% of 505 companies
in the Biotechnology industry
Industry Median: 5.24 vs BSP:VRTX34: 20.07

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Vertex Pharmaceuticals's adjusted revenue per share data for the three months ended in Dec. 2023 was R$11.825. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is R$24.14 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Vertex Pharmaceuticals Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Vertex Pharmaceuticals's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vertex Pharmaceuticals Cyclically Adjusted PS Ratio Chart

Vertex Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 29.16 23.88 17.19 17.86 20.54

Vertex Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.86 18.36 19.42 18.20 20.54

Competitive Comparison of Vertex Pharmaceuticals's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Vertex Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vertex Pharmaceuticals's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vertex Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Vertex Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.



Vertex Pharmaceuticals Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Vertex Pharmaceuticals's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=509.49/24.14
=21.11

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vertex Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Vertex Pharmaceuticals's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=11.825/129.4194*129.4194
=11.825

Current CPI (Dec. 2023) = 129.4194.

Vertex Pharmaceuticals Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201403 0.296 99.695 0.384
201406 0.331 100.560 0.426
201409 0.443 100.428 0.571
201412 0.400 99.070 0.523
201503 0.454 99.621 0.590
201506 0.537 100.684 0.690
201509 1.249 100.392 1.610
201512 1.669 99.792 2.165
201603 1.509 100.470 1.944
201606 1.511 101.688 1.923
201609 1.374 101.861 1.746
201612 1.569 101.863 1.993
201703 2.247 102.862 2.827
201706 1.781 103.349 2.230
201709 1.809 104.136 2.248
201712 2.092 104.011 2.603
201803 2.032 105.290 2.498
201806 2.742 106.317 3.338
201809 3.102 106.507 3.769
201812 3.251 105.998 3.969
201903 3.168 107.251 3.823
201906 3.492 108.070 4.182
201909 3.755 108.329 4.486
201912 5.530 108.420 6.601
202003 7.023 108.902 8.346
202006 7.507 108.767 8.932
202009 7.864 109.815 9.268
202012 8.006 109.897 9.428
202103 9.275 111.754 10.741
202106 8.638 114.631 9.752
202109 10.083 115.734 11.275
202112 11.406 117.630 12.549
202203 10.118 121.301 10.795
202206 10.713 125.017 11.090
202209 11.792 125.227 12.187
202212 11.601 125.222 11.990
202303 11.880 127.348 12.073
202306 11.618 128.729 11.680
202309 11.766 129.860 11.726
202312 11.825 129.419 11.825

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Vertex Pharmaceuticals  (BSP:VRTX34) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Vertex Pharmaceuticals Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Vertex Pharmaceuticals's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Vertex Pharmaceuticals (BSP:VRTX34) Business Description

Address
50 Northern Avenue, Boston, MA, USA, 02210
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Vertex Pharmaceuticals (BSP:VRTX34) Headlines

No Headlines